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report and review of the literatures
Yefei Rong, Dansong Wang, Wenhui Lou, Tiantao Kuang and Dayong Jin*
Abstract
Background: Granulocytic sarcoma (GS) is a form of acute myeloid leukemia (AML), also known as extramedullary 
myeloid tumor or chloroma. It forms a solid malignant tumor consisting of myelocytes or granulocytes and is typically 
located in bone while occurrence in other parts of the body is rare.
Case presentation: We reported a 40-year-old male patient who had jaundice, highly elevated bilirubin, and a mass 
highly suspicious of pancreatic head carcinoma. We performed surgery and the pathology and immunohistochemistry 
suggested GS; however the blood test and the bone marrow infiltration showed no evidence of AML. In our review of 
the published reports of GS, we only found six reports of the GS in the pancreas, and we suggested that 
immunohistochemical staining should be used to accurately differentiate GS from other pancreatic cancer and other 
types of leukemia.
Conclusions: The accurate diagnosis of GS is necessary for determining prognosis and deciding appropriate therapy.
Background
Granulocytic sarcoma (GS), also called extramedulary
myeloblastoma or chloroma, is a rare solid tumor com-
posed of immature myeloid cells [1]. The tumor may pre-
cede or occur concurrently with acute or chronic myeloid
leukaemia or less often with polycythemia vera and pri-
mary myelofibrosis. Granulocytic sarcomas usually
occurred in skin, soft tissue, lymph nodes, and bones [2].
Only few cases of GS of the pancreas had been reported
in literatures [3,4]. We hereby reported a case of GS in the
pancreas, in a patient without AML.
Case presentation
The patient was a 40-year-old man. He had no significant
past medical history. He initially went to the outside hos-
pital on Jan 20, 2009, with the symptom of jaundice and
weight loss of 5 Kg in one month. He described that his
skin and sclera got yellow and gradually got worse in one
month. He denied fever, chills, nausea, or vomiting. His
physical examination at the time was only yellow skin and
sclera. His routine laboratory test only showed the ele-
vated total bilirubin and direct bilirubin. MRCP of the
other hospital showed the malignant tumor in the distal
common bile duct.
He was referred to our department for surgical treat-
ment on Jan 24, 2009. At this time, his symptoms and
physical examination results remained unchanged.
Hemoglobin: 118g/L, white blood cell count: 3,600/mm3,
platelets: 142 × 103/mm3, AST: 114U/L, ALT: 250U/L,
total bilirubin: 43.2 μmol/L, direct bilirubin: 35.2 μmol/L,
serum creatinine:80 μmol/L,AFP:1.7ng/L,CA19-9:13.1U/
L (normal < 37U/L). A CT scan (performed as a three-
dimensional multi-detector scan) revealed a low-density
mass at the pancreatic head (Figure 1). There was no evi-
dence of ascites, and all of the peri-hepatic and peri-pan-
creatic visceral vessels were not invaded. Exploratory
laparotomy was performed because pancreatic cancer
was highly suspected.
At abdominal exploration on Feb 5, 2009, a mass was
found in the pancreatic head. So we performed Whipple
surgery. All pathology specimens were routinely pro-
cessed. Histological examination showed diffusely infil-
trating mono-morphous population of immature blast-
like cells. The cells were intermediate in size and round to
oval in shape with mild to moderate basophilic cytoplasm
without granules (Figure 2). Immunohistochemical stains
were performed on the paraffin-embedded sections. The
tumor cells demonstrated positive reaction to myeloper-
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oxidase (MPO), CD43 antibodies and negative to CD20
and CD2 monoclonal antibodies (Figure 3). Taking these
results together, a diagnosis of GS was rendered. When
the pathological results were confirmed; we performed
the bone marrow infiltration. There was no evidence of
AML. The patient was discharged on postoperative day12
in stable condition. Although the patient had no evidence
of concomitant AML, the haemologist did suggest che-
motherapy with cytarabine. The patient is followed up
and currently doing well. The blood test and bone mar-
row infiltration show no evidence of AML.
Discussions and Conclusions
Since 1966, about 1,000 cases of GS located outside bone
had been published. GS of the pancreas was extremely
rare; and only few cases were previously described. Sev-
eral chromosome rearrangements were associated with
GS, especially t (8; 21) and, less often inv (16) (p13; q22)
[5-7]. Both rearrangements involved the core binding fac-
tor (CBF) gene and associated with high rates of complete
remission and long-term disease-free survival in AML
[8,9].
In the differential diagnosis, the most important dis-
eases to be considered were non-Hodgkin lymphomas of
the lymhoblastic type, Burkitt lymphoma, large-cell lym-
phoma and small round cell tumors [10]. Diagnostic con-
firmation of GS usually required immunohistochemical
stainings for expression of myeloid associated enzymes.
In addition to MPO, lysozyme, and chloroacetate
esterase, GS usually expressed myeloid-associated anti-
gens such as CD43, CD13, CD33, and CD117, but were
negative with lymphoid antigens such as CD3 and
CD20.Traweek et al[11] found that the use of an immuno-
histochemical panel including CD20, CD43, CD68, and
MPO could successfully identify the vast majority of GS
(90%).
For the treatment of the GS, radiation therapy or surgi-
cal resection had been found less effective than chemo-
therapy on improving the disease-free interval or disease-
free survival [2,3]. Therefore it was very important for
correct diagnosis of GS. As for GS might occur simulta-
neously with leukemia, the mass in these patients should
be suspicious of GS and perhaps the fine needle biopsy
should be performed before surgery or radiation therapy.
However some patients with GS had no concomitant
symptoms of leukemia, these patients were initially mis-
diagnosed. Nonleukemic patients who present with GS,
most will develop AML within 1 year (median 5 months).
For patients with known myeloproliferative disorders, the
development of GS was a strongly negative prognostic
factor for AML. Overall, the median survival was 7-20
months after the diagnosis of GS [12,13]. Once the diag-
nosis of GS had been confirmed by pathology and immu-
nohistochemistry, the patients should be treated with
chemotherapy even for the patients who had no concom-
itant leukemia.
Consent
The patient has given their consent for the case report to
be published. Written informed consent was obtained
Figure 1 Abdominal computed tomography. Abdominal comput-
ed tomography showed a low density mass at the pancreatic head (ar-
rows).
Figure 2 Hematoxylin-eosin staining of the pancreatic GS. HE 
staining showed the infiltration of pancreas by immature neoplastic 
myeloid cells.
Figure 3 Immunohistochemistry of the pancreatic GS. (A) immu-
nohistochemical detection of myeloperoxidase. Myeloid cells show 
strong positive signal; (B) immunohistochemical detection of CD43. 
Myeloid cells show strong positive signal.Rong et al. BMC Gastroenterology 2010, 10:80
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from the patient for publication of this case report and
any accompanying images. A copy of the written consent
is available for review by the Editor-in-Chief of this jour-
nal.
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